Reuters logo
BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
October 19, 2017 / 10:03 PM / in a month

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

Oct 20 (Reuters) - Durect Corp

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

* Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​

* Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below